Exane Derivatives’s Kansas City Southern KSU Stock Holding History

Exane Derivatives’s Portfolio KSU Stock Details KSU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4	Closed	-$1.08K	–	1118
2021 Q3	$1.08K	Hold	4	–	–	﹤0.01%	855
2021 Q2	$1.07K	Hold	4	–	–	﹤0.01%	865
2021 Q1	$1.06K	Hold	4	–	–	﹤0.01%	730
2020 Q4	$816	Hold	4	–	–	﹤0.01%	695
2020 Q3	$723	Hold	4	–	–	﹤0.01%	650
2020 Q2	$597	Hold	4	–	–	﹤0.01%	595
2020 Q1	$509	Hold	4	–	–	﹤0.01%	596
2019 Q4	$639	Sell	4 -7	-64%	-$1.03K	﹤0.01%	589
2019 Q3	$1.46K	Hold	11	–	–	﹤0.01%	515
2019 Q2	$1.34K	Buy	11 +8	+267%	+$957	﹤0.01%	541
2019 Q1	$348	Hold	3	–	–	﹤0.01%	557
2018 Q4	$286	Sell	3 -1	-25%	-$102	﹤0.01%	622
2018 Q3	$456	Hold	4	–	–	﹤0.01%	577
2018 Q2	$428	Hold	4	–	–	﹤0.01%	571
2018 Q1	$430	Sell	4 -34	-89%	-$3.68K	﹤0.01%	515
2017 Q4	$4K	Buy	+38	New	+$4.05K	﹤0.01%	435

Other funds holding KSU

Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return

FCB

First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

JAM

JCIC Asset Management Toronto, Ontario, Canada $326M AUM 31.94% 1-Year Est. Return

Exane Derivatives's KSU Position: Q4 2021 in Review

Exane Derivatives sold out of Kansas City Southern (KSU) in Q4 2021, closing a stake of 4 shares — an estimated $1.08K sold.

Exane Derivatives first reported a position in KSU in Q4 2017 and held it in 16 quarters. The position peaked at $4K in Q4 2017. 4 funds tracked by Wall St. Rank hold KSU as of Q4 2021.

Exane Derivatives reported no remaining Kansas City Southern position as of Q4 2021 after selling out during the quarter.
Exane Derivatives sold 4 Kansas City Southern shares in Q4 2021, an estimated $1.08K.
Exane Derivatives first reported a position in Kansas City Southern in Q4 2017 and held it in 16 quarters.
Exane Derivatives's Kansas City Southern position peaked at $4K in Q4 2017.
4 funds tracked by Wall St. Rank held Kansas City Southern as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.